Advertisement
Reviews and Perspectives Reviews in Basic and Clinical Gastroenterology and Hepatology| Volume 152, ISSUE 6, P1297-1309, May 01, 2017

Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions

  • Rohit Loomba
    Correspondence
    Rohit Loomba, MD, MHSc, Division of Gastroenterology, Department of Medicine, University of California at San Diego, 9500 Gilman Drive, BRF-II-4A-18, La Jolla, California 92093-0063.
    Affiliations
    Division of Gastroenterology, Department of Medicine, University of California at San Diego, La Jolla, California
    Search for articles by this author
  • T. Jake Liang
    Correspondence
    Reprint requests Address requests for reprints to: T. Jake Liang, MD, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 10 Center Drive, Building 9B-16, Bethesda, Maryland 20892. fax: 1-301-402-0491.
    Affiliations
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    Search for articles by this author
Published:February 17, 2017DOI:https://doi.org/10.1053/j.gastro.2017.02.009
      Hepatitis B reactivation associated with immune-suppressive and biological therapies is emerging to be an important cause of morbidity and mortality in patients with current or prior exposure to hepatitis B virus (HBV) infection. The population at risk for HBV reactivation includes those who either currently are infected with HBV or have had past exposure to HBV. Because curative and eradicative therapy for HBV is not currently available, there is a large reservoir of individuals at risk for HBV reactivation in the general population. HBV reactivation with its potential consequences is particularly a concern when these people are exposed to either cancer chemotherapy, immunosuppressive or biologic therapies for the management of rheumatologic conditions, malignancies, inflammatory bowel disease, dermatologic conditions, or solid-organ or bone marrow transplantation. With the advent of newer and emerging forms of targeted biologic therapies, it has become important to understand the mechanisms whereby certain therapies are more prone to HBV reactivation. This review provides a comprehensive update on the current concepts, risk factors, molecular mechanisms, prevention, and management of hepatitis B reactivation. In addition, we provide recommendations for future research in this area.

      Keywords

      Abbreviations used in this paper:

      ALT (alanine aminotransferase), anti-HBs (antibody to hepatitis B surface antigen), AST (aspartate aminotransferase), cccDNA (covalently closed circular DNA), CHB (chronic hepatitis B), HBc (hepatitis B core), HBsAg (hepatitis B surface antigen), HBV (hepatitis B virus), HDI (histone deacetylase inhibitor), TNF-α (tumor necrosis factor-α)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Dienstag J.L.
        Hepatitis B virus infection.
        N Engl J Med. 2008; 359: 1486-1500
        • Liang T.J.
        • Block T.M.
        • McMahon B.J.
        • et al.
        Present and future therapies of hepatitis B: from discovery to cure.
        Hepatology. 2015; 62: 1893-1908
        • Hoofnagle J.H.
        Reactivation of hepatitis B.
        Hepatology. 2009; 49: S156-S165
        • Doo E.C.
        • Hoofnagle J.H.
        • Rodgers G.P.
        NIH consensus development conference: management of hepatitis B.
        Introduction. Hepatology. 2009; 49: S1-S3
        • Di Bisceglie A.M.
        • Lok A.S.
        • Martin P.
        • et al.
        Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?.
        Hepatology. 2015; 61: 703-711
        • Lok A.S.
        • Ward J.W.
        • Perrillo R.P.
        • et al.
        Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable.
        Ann Intern Med. 2012; 156: 743-745
        • Nagington J.
        Reactivation of hepatitis b after transplantation operations.
        Lancet. 1977; 1: 558-560
        • Hwang J.P.
        • Vierling J.M.
        • Zelenetz A.D.
        • et al.
        Hepatitis B virus management to prevent reactivation after chemotherapy: a review.
        Support Care Cancer. 2012; 20: 2999-3008
        • Perrillo R.P.
        • Gish R.
        • Falck-Ytter Y.T.
        American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.
        Gastroenterology. 2015; 148: 221-244 e3
        • Reddy K.R.
        • Beavers K.L.
        • Hammond S.P.
        • et al.
        American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.
        Gastroenterology. 2015; 148 (quiz e16–e17): 215-219
        • Loomba R.
        • Rowley A.
        • Wesley R.
        • et al.
        Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy.
        Ann Intern Med. 2008; 148: 519-528
        • Yeo W.
        • Chan P.K.
        • Zhong S.
        • et al.
        Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.
        J Med Virol. 2000; 62: 299-307
        • Yeo W.
        • Chan P.K.
        • Ho W.M.
        • et al.
        Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.
        J Clin Oncol. 2004; 22: 927-934
        • Yeo W.
        • Chan P.K.
        • Hui P.
        • et al.
        Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study.
        J Med Virol. 2003; 70: 553-561
        • Yeo W.
        • Johnson P.J.
        Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.
        Hepatology. 2006; 43: 209-220
        • Lok A.S.
        • McMahon B.J.
        Chronic hepatitis B: update 2009.
        Hepatology. 2009; 50: 661-662
        • Tohme R.A.
        • Bulkow L.
        • Homan C.E.
        • et al.
        Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B-Alaska, 2001-2010.
        J Clin Virol. 2013; 58: 396-400
        • Borentain P.
        • Colson P.
        • Coso D.
        • et al.
        Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.
        J Viral Hepat. 2010; 17: 807-815
        • Hayashi K.
        • Ishigami M.
        • Ishizu Y.
        • et al.
        Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy.
        J Gastroenterol. 2016; 51: 1081-1089
        • Puoti M.
        • Torti C.
        • Bruno R.
        • et al.
        Natural history of chronic hepatitis B in co-infected patients.
        J Hepatol. 2006; 44: S65-S70
        • De Monte A.
        • Courjon J.
        • Anty R.
        • et al.
        Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge.
        J Clin Virol. 2016; 78: 27-30
        • Koh C.
        • Canini L.
        • Dahari H.
        • et al.
        Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.
        Lancet Infect Dis. 2015; 15: 1167-1174
        • Evens A.M.
        • Jovanovic B.D.
        • Su Y.C.
        • et al.
        Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports.
        Ann Oncol. 2011; 22: 1170-1180
        • Mozessohn L.
        • Chan K.K.
        • Feld J.J.
        • et al.
        Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis.
        J Viral Hepat. 2015; 22: 842-849
        • Paul S.
        • Saxena A.
        • Terrin N.
        • et al.
        Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis.
        Ann Intern Med. 2016; 164: 30-40
        • Kim M.K.
        • Ahn J.H.
        • Kim S.B.
        • et al.
        Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience.
        Korean J Intern Med. 2007; 22: 237-243
        • Esteve M.
        • Saro C.
        • Gonzalez-Huix F.
        • et al.
        Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.
        Gut. 2004; 53: 1363-1365
        • Lan J.L.
        • Chen Y.M.
        • Hsieh T.Y.
        • et al.
        Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
        Ann Rheum Dis. 2011; 70: 1719-1725
        • Chung S.J.
        • Kim J.K.
        • Park M.C.
        • et al.
        Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy.
        J Rheumatol. 2009; 36: 2416-2420
        • Fanouriakis A.
        • Vassilopoulos D.
        • Repa A.
        • et al.
        Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection.
        Rheumatology (Oxford). 2014; 53: 195-196
        • Kato M.
        • Atsumi T.
        • Kurita T.
        • et al.
        Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in hepatitis B surface antigen-negative cases.
        J Rheumatol. 2011; 38: 2209-2214
        • Lee Y.H.
        • Bae S.C.
        • Song G.G.
        Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
        Clin Exp Rheumatol. 2013; 31: 118-121
        • Perez-Alvarez R.
        • Diaz-Lagares C.
        • Garcia-Hernandez F.
        • et al.
        Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases.
        Medicine (Baltimore). 2011; 90: 359-371
        • Koskinas J.
        • Tampaki M.
        • Doumba P.P.
        • et al.
        Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient.
        Br J Dermatol. 2013; 168: 679-680
        • Nakano N.
        • Kusumoto S.
        • Tanaka Y.
        • et al.
        Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab.
        Hepatol Res. 2014; 44: 354-357
        • Ikeda K.
        • Shiga Y.
        • Takahashi A.
        • et al.
        Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment.
        Leuk Lymphoma. 2006; 47: 155-157
        • Lai G.M.
        • Yan S.L.
        • Chang C.S.
        • et al.
        Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor.
        World J Gastroenterol. 2013; 19: 1318-1321
        • Lakhani S.
        • Davidson L.
        • Priebat D.A.
        • et al.
        Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy.
        Hepatol Int. 2008; 2: 498-499
        • Beysel S.
        • Yegin Z.A.
        • Yagci M.
        Bortezomib-associated late hepatitis B reactivation in a case of multiple myeloma.
        Turk J Gastroenterol. 2010; 21: 197-198
        • Li J.
        • Huang B.
        • Li Y.
        • et al.
        Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant.
        Leuk Lymphoma. 2015; 56: 1710-1717
        • Ritchie D.
        • Piekarz R.L.
        • Blombery P.
        • et al.
        Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report.
        Haematologica. 2009; 94: 1618-1622
        • Yeo W.
        • Zee B.
        • Zhong S.
        • et al.
        Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy.
        Br J Cancer. 2004; 90: 1306-1311
        • Calabrese L.H.
        • Zein N.N.
        • Vassilopoulos D.
        Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies.
        Ann Rheum Dis. 2006; 65: 983-989
        • Kudo M.
        Immune checkpoint blockade in hepatocellular carcinoma: 2017 update.
        Liver Cancer. 2016; 6: 1-12
        • Seeger C.
        • Mason W.S.
        Molecular biology of hepatitis B virus infection.
        Virology. 2015; 479–480: 672-686
        • Yan H.
        • Zhong G.
        • Xu G.
        • et al.
        Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus.
        Elife. 2012; 1: e00049
        • Bock C.T.
        • Schwinn S.
        • Locarnini S.
        • et al.
        Structural organization of the hepatitis B virus minichromosome.
        J Mol Biol. 2001; 307: 183-196
        • Pollicino T.
        • Belloni L.
        • Raffa G.
        • et al.
        Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones.
        Gastroenterology. 2006; 130: 823-837
        • Belloni L.
        • Pollicino T.
        • De Nicola F.
        • et al.
        Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function.
        Proc Natl Acad Sci U S A. 2009; 106: 19975-19979
        • Seeger C.
        • Mason W.S.
        Hepatitis B virus biology.
        Microbiol Mol Biol Rev. 2000; 64: 51-68
        • Rehermann B.
        • Ferrari C.
        • Pasquinelli C.
        • et al.
        The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.
        Nat Med. 1996; 2: 1104-1108
        • Werle-Lapostolle B.
        • Bowden S.
        • Locarnini S.
        • et al.
        Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.
        Gastroenterology. 2004; 126: 1750-1758
        • Sung J.J.
        • Wong M.L.
        • Bowden S.
        • et al.
        Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy.
        Gastroenterology. 2005; 128: 1890-1897
        • Zhu Y.
        • Yamamoto T.
        • Cullen J.
        • et al.
        Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis.
        J Virol. 2001; 75: 311-322
        • Rehermann B.
        Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells.
        Nat Med. 2013; 19: 859-868
        • Guidotti L.G.
        • Chisari F.V.
        Immunobiology and pathogenesis of viral hepatitis.
        Annu Rev Pathol. 2006; 1: 23-61
        • Maini M.K.
        • Gehring A.J.
        The role of innate immunity in the immunopathology and treatment of HBV infection.
        J Hepatol. 2016; 64: S60-S70
        • Lowenberg M.
        • Verhaar A.P.
        • van den Brink G.R.
        • et al.
        Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression.
        Trends Mol Med. 2007; 13: 158-163
        • Azzi J.R.
        • Sayegh M.H.
        • Mallat S.G.
        Calcineurin inhibitors: 40 years later, can't live without.
        J Immunol. 2013; 191: 5785-5791
        • Bandzar S.
        • Gupta S.
        • Platt M.O.
        Crohn's disease: a review of treatment options and current research.
        Cell Immunol. 2013; 286: 45-52
        • Hwang Y.G.
        • Moreland L.W.
        Induction therapy with combination TNF inhibitor and methotrexate in early rheumatoid arthritis.
        Curr Rheumatol Rep. 2014; 16: 417
        • Lucifora J.
        • Xia Y.
        • Reisinger F.
        • et al.
        Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.
        Science. 2014; 343: 1221-1228
        • Pers Y.M.
        • Jorgensen C.
        Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases.
        Immunotherapy. 2016; 8: 1091-1096
        • Engelhard M.
        Anti-CD20 antibody treatment of non-Hodgkin lymphomas.
        Clin Immunol. 2016; 172: 101-104
        • Dokmanovic M.
        • Clarke C.
        • Marks P.A.
        Histone deacetylase inhibitors: overview and perspectives.
        Mol Cancer Res. 2007; 5: 981-989
        • Chueh A.C.
        • Tse J.W.
        • Togel L.
        • et al.
        Mechanisms of histone deacetylase inhibitor-regulated gene expression in cancer cells.
        Antioxid Redox Signal. 2015; 23: 66-84
        • Tropberger P.
        • Mercier A.
        • Robinson M.
        • et al.
        Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation.
        Proc Natl Acad Sci U S A. 2015; 112: E5715-E5724
        • Abram C.L.
        • Lowell C.A.
        The ins and outs of leukocyte integrin signaling.
        Annu Rev Immunol. 2009; 27: 339-362
        • Marra F.
        • Tacke F.
        Roles for chemokines in liver disease.
        Gastroenterology. 2014; 147: 577-594 e1
        • Rowinsky E.K.
        The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors.
        Annu Rev Med. 2004; 55: 433-457
        • Khokhar O.S.
        • Farhadi A.
        • McGrail L.
        • et al.
        Oncologists and hepatitis B: a survey to determine current level of awareness and practice of antiviral prophylaxis to prevent reactivation.
        Chemotherapy. 2009; 55: 69-75
        • European Association for the Study of the Liver
        EASL clinical practice guidelines: management of chronic hepatitis B virus infection.
        J Hepatol. 2012; 57: 167-185
        • Hwang J.P.
        • Somerfield M.R.
        • Alston-Johnson D.E.
        • et al.
        Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update.
        J Clin Oncol. 2015; 33: 2212-2220
        • Sarin S.K.
        • Kumar M.
        • Lau G.K.
        • et al.
        Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.
        Hepatol Int. 2016; 10: 1-98
        • Saab S.
        • Dong M.H.
        • Joseph T.A.
        • et al.
        Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model.
        Hepatology. 2007; 46: 1049-1056
        • Kohrt H.E.
        • Ouyang D.L.
        • Keeffe E.B.
        Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection.
        Aliment Pharmacol Ther. 2006; 24: 1003-1016
        • Huang H.
        • Li X.
        • Zhu J.
        • et al.
        Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
        JAMA. 2014; 312: 2521-2530
        • Hilgendorf I.
        • Loebermann M.
        • Borchert K.
        • et al.
        Tenofovir for treatment of hepatitis B virus reactivation in patients with chronic GVHD.
        Bone Marrow Transplant. 2011; 46: 1274-1275
        • Chen W.C.
        • Cheng J.S.
        • Chiang P.H.
        • et al.
        A comparison of entecavir and lamivudine for the prophylaxis of hepatitis B virus reactivation in solid tumor patients undergoing systemic cytotoxic chemotherapy.
        PLoS One. 2015; 10: e0131545
        • Huang Y.H.
        • Hsiao L.T.
        • Hong Y.C.
        • et al.
        Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
        J Clin Oncol. 2013; 31: 2765-2772
        • Ho E.Y.
        • Yau T.
        • Rousseau F.
        • et al.
        Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.
        Hepatol Int. 2015; 9: 224-230
        • Zhang M.Y.
        • Zhu G.Q.
        • Shi K.Q.
        • et al.
        Systematic review with network meta-analysis: comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.
        Oncotarget. 2016; 7: 30642-30658
        • Zurawska U.
        • Hicks L.K.
        • Woo G.
        • et al.
        Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis.
        J Clin Oncol. 2012; 30: 3167-3173
        • Wong W.W.
        • Hicks L.K.
        • Tu H.A.
        • et al.
        Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis.
        Breast Cancer Res Treat. 2015; 151: 639-652
        • Visram A.
        • Chan K.K.
        • McGee P.
        • et al.
        Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening.
        PLoS One. 2015; 10: e0120749
        • Ceccarelli L.
        • Salpini R.
        • Sarmati L.
        • et al.
        Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy.
        J Infect. 2012; 65: 180-183
        • Myers R.P.
        • Swain M.G.
        • Urbanski S.J.
        • et al.
        Reactivation of hepatitis B e antigen-negative chronic hepatitis B in a bone marrow transplant recipient following lamivudine withdrawal.
        Can J Gastroenterol. 2001; 15: 599-603